Literature DB >> 20362848

Outcomes of reenclavation of subluxated iris-fixated phakic intraocular lenses: comparison with primary surgery outcomes.

Jeewan S Titiyal1, Namrata Sharma, Rashim Mannan, Archna Pruthi, Rasik B Vajpayee.   

Abstract

PURPOSE: To study the outcomes of successful reenclavation of subluxated iris-fixated phakic intraocular lenses (pIOLs).
SETTING: Tertiary eyecare referral center.
METHODS: Interventional case series comprised eyes with a subluxated Verisyse pIOL that had successful reenclavation of 1 haptic. A comparison of outcomes between primary pIOL implantation surgery and subsequent reenclavation was performed. The parameters were uncorrected (UDVA) and corrected (CDVA) distance visual acuity and the quantitative endothelial changes preoperatively and postoperatively at 1 week and 1, 3, and 6 months.
RESULTS: Nine eyes of 6 patients were evaluated. Disenclavation was spontaneous in 6 eyes (66.6%) and posttraumatic in 3 eyes (33.3%). The mean UDVA and CDVA at 6 months were comparable between primary surgery and reenclavation. The subluxation and subsequent reenclavation did not cause statistically significant endothelial cell loss; endothelial cell loss after reenclavation was comparable to that after primary surgery (P = .953).
CONCLUSION: Successful subluxation of iris-fixated pIOLs did not cause significant damage to the ocular structures or lead to serious complications. Copyright (c) 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362848     DOI: 10.1016/j.jcrs.2009.11.004

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  1 in total

1.  Myopic Correction with Iris-Fixated Phakic Intraocular Lenses: Twelve-Year Results.

Authors:  Iveta Nemcova; Jiri Pasta; Katerina Hladikova; Martin Komarc; Darina Pospisilova; Pavel Nemec; Jan Tesar; Vladimir Kratky; Martin Sin
Journal:  J Ophthalmol       Date:  2021-10-07       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.